Arrowhead Pharmaceuticals Inc (ARWR) COO Bruce D. Given Sells 20,000 Shares

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) COO Bruce D. Given sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, January 1st. The shares were sold at an average price of $3.69, for a total value of $73,800.00. Following the completion of the sale, the chief operating officer now directly owns 948,356 shares of the company’s stock, valued at $3,499,433.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of Arrowhead Pharmaceuticals Inc (NASDAQ ARWR) traded up $0.92 during midday trading on Thursday, reaching $4.64. The company’s stock had a trading volume of 5,874,600 shares, compared to its average volume of 3,326,450. The firm has a market cap of $367.78, a PE ratio of -9.87 and a beta of 1.79. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.63 and a quick ratio of 3.63. Arrowhead Pharmaceuticals Inc has a 52-week low of $1.42 and a 52-week high of $4.88.

Several analysts recently weighed in on ARWR shares. William Blair raised Arrowhead Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Monday, September 18th. Piper Jaffray Companies raised Arrowhead Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $5.50 price target for the company in a report on Monday, November 27th. Cantor Fitzgerald reissued a “hold” rating and set a $2.00 price target (up from $1.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, September 15th. Chardan Capital reissued a “neutral” rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, September 13th. Finally, ValuEngine raised Arrowhead Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, November 30th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $3.17.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Allianz Asset Management GmbH acquired a new position in Arrowhead Pharmaceuticals in the 3rd quarter valued at $1,958,000. Dimensional Fund Advisors LP raised its holdings in Arrowhead Pharmaceuticals by 252.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 44,358 shares of the biotechnology company’s stock valued at $192,000 after acquiring an additional 31,765 shares in the last quarter. Schwab Charles Investment Management Inc. raised its holdings in Arrowhead Pharmaceuticals by 10.4% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 171,249 shares of the biotechnology company’s stock valued at $742,000 after acquiring an additional 16,103 shares in the last quarter. ING Groep NV acquired a new position in Arrowhead Pharmaceuticals in the 3rd quarter valued at $3,500,000. Finally, Virtu KCG Holdings LLC raised its holdings in Arrowhead Pharmaceuticals by 115.6% in the 2nd quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock valued at $161,000 after acquiring an additional 53,215 shares in the last quarter. 20.05% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This story was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.chaffeybreeze.com/2018/01/04/arrowhead-pharmaceuticals-inc-arwr-coo-bruce-d-given-sells-20000-shares.html.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply